Inhibrx, Inc. (NASDAQ:INBX) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP grew its holdings in Inhibrx, Inc. (NASDAQ:INBX) by 24.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 174,899 shares of the company’s stock after acquiring an additional 34,310 shares during the quarter. Wellington Management Group LLP owned 0.37% of Inhibrx worth $3,209,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. RA Capital Management L.P. boosted its holdings in Inhibrx by 22.6% in the third quarter. RA Capital Management L.P. now owns 4,724,207 shares of the company’s stock worth $86,689,000 after acquiring an additional 870,340 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in Inhibrx by 9.1% in the first quarter. Perceptive Advisors LLC now owns 3,615,383 shares of the company’s stock worth $68,222,000 after acquiring an additional 301,600 shares in the last quarter. BlackRock Inc. boosted its holdings in Inhibrx by 9.2% in the second quarter. BlackRock Inc. now owns 2,546,603 shares of the company’s stock worth $66,110,000 after acquiring an additional 213,678 shares in the last quarter. State Street Corp boosted its holdings in Inhibrx by 282.7% in the third quarter. State Street Corp now owns 2,040,054 shares of the company’s stock worth $36,619,000 after acquiring an additional 1,506,986 shares in the last quarter. Finally, Woodline Partners LP boosted its holdings in Inhibrx by 385.3% in the second quarter. Woodline Partners LP now owns 1,524,915 shares of the company’s stock worth $39,587,000 after acquiring an additional 1,210,720 shares in the last quarter. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Price Performance

Shares of NASDAQ INBX opened at $35.15 on Thursday. The business’s 50 day moving average price is $36.57 and its 200 day moving average price is $27.97. The firm has a market cap of $1.67 billion, a P/E ratio of -6.99 and a beta of 2.94. Inhibrx, Inc. has a 52 week low of $14.31 and a 52 week high of $39.79. The company has a quick ratio of 5.25, a current ratio of 5.24 and a debt-to-equity ratio of 4.78.

Inhibrx (NASDAQ:INBX) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.66). Inhibrx had a negative return on equity of 590.78% and a negative net margin of 13,408.95%. The company had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, sell-side analysts expect that Inhibrx, Inc. will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

INBX has been the topic of a number of recent research reports. Lifesci Capital lowered Inhibrx from an “outperform” rating to a “market perform” rating in a research report on Tuesday, January 23rd. JMP Securities reiterated a “market perform” rating on shares of Inhibrx in a research report on Tuesday, January 23rd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.